industri incorpor buy pt initi buy rate pt base momentum
integr energi effici facil manag contract analyst tate sullivan cfa full summari
azurrx biopharma inc azrx buy pt lower pill burden improv qol exocrin pancreat insuffici
initi coverag buy rate pt analyst carolin palomequ full summari
inc buy pt debt financ could extend runway bivgam approv
analyst jason mccarthi ph full summari
inc buy pt shutdown china impact januari strateg posit leav mid long-term
teva pharmaceut industri ltd teva hold progress continu still tough ahead teva
outlook street-high ep estim maintain buy pt analyst tate sullivan cfa full summari
ellington llc buy pt convers reit taxabl year help stock price
liquid reiter buy pt analyst michael diana full summari
veru inc veru buy pt report quarter updat prostat cancer program analyst jason
corpor event call maxim salesperson inform
charl colvard ltd cthr ndr new york ceo/presid suzann miglucci cfo clint pete tue feb
custom inc cover diana ndr connecticut ceo jay sidhu tue march
brainstorm cell bcli cover palomequ ndr nyc ceo chief execut offic
ralph kern cfo eyal rubin wed-thu feb
bioporto a/ biopor ndr new york ceo peter morch cfo ole larson fri feb
biotim inc cover mccarthi ndr nyc ceo brian culley cfo brandi robert tue feb
intec pharma ntec cover mccarthi kol dinner nyc ceo jeffrey meckler dr karl kierbutz dr
cover sullivan ndr boston ceo denni sadlowski cfo matthew
stealthga inc gass cover jang ndr nyc ceo harri vafia tue
genco ship trade ltd cover jang ndr chicago ceo john wobensmith cfo
navig hold ltd nvg cover jang group luncheon new york ceo david butter thu
pm
cover jang ndr boston ceo gari vogel cfo frank decostanzo
director strategi busi develop costa tsoutsoplid tue apr
inc cover confer call cfo tonya robinson director
financi analysi michael bailen mon pm et
sifi technolog limit sifi cover klee ndr nyc svp financ gangadharan venugop wed
agilysi inc cover klee ndr chicago cfo toni pritchett vice-president financ dave wood thu
univers mcloud corpor mcld cover chokshi ndr greater miami ceo russ mcmeekin wed
cover klee ndr chicago presid ceo michael prior cfo justin
cover klee ndr milwauke presid ceo michael prior cfo
inc cover klee ndr nyc ceo steve picket cfo ahlstrom tue apr
inc cover klee ndr boston ceo steve picket cfo ahlstrom wed apr
inc cover klee ndr milwauke ceo steve picket cfo ahlstrom thu apr
initi buy rate pt base
momentum integr effici facil
make effici continu integr energi
effici project exist facil manag contract larg
custom cut cost use bundl offer instead
award intern infrastructur support contract differ compani
announc nine energi effici project januari
seven
one reason bought gca servic billion
largest acquisit ever sell energi effici project client
run school view
increas debt acquir gca labor intens janitori servic
work caus short interest increas last year view
janitor contract current major sale profit
help sell energi effici project facil servic believ
energi effici work help compani get work facil even
though contract opportun today base competit bid process
believ facil start recogn use variou facil
servic includ energi effici save money oppos award
contract differ vendor bundl solut client accept
believ abl increas margin achiev consist revenu
growth work multipl end-market grow time
reduc debt forecast base consist free cash
flow supplement oper earn growth project ep
compound annual growth rate note forecast end
million cash even reduc debt million continu increas
dividend everi year note gener last year
increas million outflow
gaap ep forecast high-end
guidanc consensu guidanc gaap ep
base part forecast higher margin energi effici project
forecast gaap ep high-end guidanc
gaap ep consensu
custom concentr multipl end market higher margin
energi effici work support valuat gaap
ep forecast initi coverag buy rate price
target base gaap ep estim anticip
sell servic increas margin recogn integr
facil manag offer multipl industri resili earn
cyclic downturn believ share price anticip ep least
target pe multipl slight premium averag multipl
peer group includ busi servic compani energi effici
contractor account competit advantag offer energi effici
work facil servic concern increas debt labor-intens
janitori servic estim sale took short interest
last year overblown view cash flow pay
debt expertis broaden servic offer
click full note
lower pill burden improv qol exocrin
pancreat insuffici initi coverag buy
rate pt
initi coverag azurrx biopharma buy rate
price target compani lead candid oral non-anim
deriv recombin lipas enzym treatment exocrin pancreat
insuffici epi cystic fibrosi cf chronic pancreat cp
azurrx priorit develop cf first follow cp
regulatori path use approv standard care soc porcin
pancreat enzym ppe pancreat enzym replac therapi
pert posit data demonstr cp option studi
cf on-going data expect
differenti ppe space consist lipas
amylas proteas soc ppe data thu far
achiev compar efficaci reduct daili pill burden pill
per day vs soc requir pill per day ppe market us
conclus pert market rel undifferenti new entrant
would first non-porcin product avail epi
lower pill burden reduc risk allerg reaction improv qualiti life
qol on-going data read repres signific catalyst
azrx share drive higher valuat
exocrin pancreat insuffici epi character defici pancreat
enzym amylas proteas lipas requir digest gut
standard care pancreat enzym replac therapi pert via oral porcine-
deriv pancreat enzym ppe challeng enzym modestli
activ low ph acid gut thu patient need ingest pill
day particularli problemat young children cystic fibrosi cf
epi clinic development- phase data cp demonstr
favor safeti profil advers event pre-specifi
analysi show dose-depend improv fat digest compar
ppe work establish scientif rational develop cf
phase option studi cf on-going safeti primari endpoint
data expect
recombin yeast-deriv lipas amylas proteas
bodi suffici supplement enzym display acid-resist
properti allow greater enzymat activ relev acid condit
gut ph healthi patient ph patholog patient vitro test
shown effect ppe ph ph result
expect pill burden reduc pill per day ppe
pill per day pert make market us domin
porcine-deriv enzym ppe like nr creon pancrelipas
janssen nr licens pancreaz vivu vvu nr
space grow compound-annual-growth-rate still earli stage
may reduc pill burden reduc risk associ animal-deriv ppe improv
valuat model commerci exocrin pancreat
insuffici cystic fibrosi follow chronic pancreat
risk adjust appli therapeut model base stage
develop clinic trial risk factor factor
discount appli free discount ep sum-of-the-part
model equal weight deriv price target
click full note
shutdown china impact januari strateg
posit leav mid long-term guidanc
januari quarter impact us govern shutdown global busi
exposur china
april quarter initi guidanc reflect manag confid
remain well-posit mid-singl digit y/i growth view
reiter buy rate price target due differenti
januari quarter impact us govern shutdown global busi
exposur china report januari quarter revenu
y/i low end guidanc rang
product revenu y/i miss consensu estim
manag note demand proceed within expect
end decemb estim product revenu
plan month januari manag note due larg
custom industri specif exposur china public sector becom
increment cautiou note revenu direct channel
y/i tend correspond largest enterpris custom thu
support manag content also note hold
signific custom believ continu one clearli
less estim revenu thu believ
slow capital-expenditure follow disappoint dec result
publicli note result slowdown revenu china like repres
signific portion slowdown observ top-lin result
disappoint gm y/i high end guidanc
rang manag note improv
sale disciplin respect discount off-set fx headwind opex
also lower expect estim lower
consensu manag continu success drive process transform
result greater organiz effici result strong sale disciplin
 oper disciplin ep guidanc rang
april quarter initi guidanc reflect manag confid
remain well posit mid-singl digit y/i growth view april
quarter guidanc revenu consensu
midpoint revenu flat y/i impli product revenu flat y/i slight
deceler y/i growth januari quarter cfo ron pasek also
mention expect guidanc remain consist mid-term
april analyst day guidanc mid-singl digit y/i revenu growth mid-teen
ep growth given analysi indic product revenu month
januari like y/i vs expect y/i believ
midpoint guidanc emb improv demand april quarter progress
believ underpin expect y/i trajectori improv
cours april quarter respect larg custom remain
deepli involv strateg plan purchas process good
visibl deploy fit custom
reiter buy rate price target due differenti
hybrid cloud stori despit weak jan result believ guidanc paramet
suggest remain secular growth stori fortifi channel check
indic ntap lead cloud servic provid prove sustain multilay
technolog differenti extern storag array rel emc
fujitsu enabl on-going premis storag market share gain evid
custom becom commit util pay premium price
softwar technolog reduc revenu estim
 respect given jan apr miss howev ep estim
larg unchang result lower expect januari quarter opex
share count flow result price target
remain unchang base multipl take
account acquisit add back net cash-per-share discount back two year
weight cost capit wacc
click full note
outlook street-high ep estim maintain buy
market manag earlier week continu
recommend buy share base part uniqu energi deliveri
busi mix includ ownership interst natur ga pipelin
recommend buy next earn report februari
dividend increas may forecast
identifi anoth compani similar strateg
natur ga propan variou state either above-averag
instanc sussex counti natur ga distribut servic
territori delawar florida popul growth recent
 censu data compar total popul growth less
futur project help continu grow includ anoth expans
interst natur ga pipelin bring ga pennsylvania
delawar state new natur ga distribut infrastructur
florida view
sourc futur ep growth includ expand state
new compress natur ga cng busi propan offer
run variou energi deliveri busi continu help identifi
invest grow ep greater view continu
expect grow ep least base
continu identifi energi deliveri project acquisit instanc
del-mar pathway project western palm beach counti
expans gener new ep base review
current project support street-high ep estim maintain
ep estim consensu least
five project gener net incom current expect
million increment gross margin million separ
project list growth project compani present expect
continu natur ga commun ga system cg propan
custom growth beyond
continu expect least ep growth next earn
report announc march growth project togeth organ
custom growth lead ep growth least per share
current guidanc impli ep higher compar
ep forecast consensu forecast oper incom
grow million base higher margin
unregul busi due part cg system
maintain buy rate price target price target base
ep estim appli premium multipl compar peer
group averag current forward pe multipl ep estim
account uniqu busi mix believ continu
lead above-averag ep dividend growth util sector
click full note
convers reit taxabl year help
stock price liquid reiter buy pt
meet analyst januari manag indic
convers reit statu feder incom tax purpos probabl
time qualifi reit dividend treatment entir yesterday
manag follow plan elect tax reit
effect januari dividend receiv tax
ordinari incom tax rate accompani
instead schedul
expect convers result higher stock price first
larger univers potenti sharehold retail investor
want institut investor permit
invest guidelin take secondli reit
elig inclus indic could possibl place russel
may index
convers reit also provid liquidity/trad volum
maintain price target price target equat
book valu view mortgag reit trade
valuat level book valu current environ
page earn model
result schedul februari post-clos
reiter buy rate next four quarter expect dividend yield
stock price appreci price target
result estim total return
click full note
progress continu still tough ahead teva
revenu mostli in-line estim vs
consensu bottom line non-gaap ep vs
howev guidanc expect per manag
trough teva busi teva end period
cash debt nonetheless compani make progress
view restructur program take time share
follow earn call morn
good ajovi launch progress well despit limit revenu
compani current neutral brand market share
normal weekli count compani anticip
austedo continu grow sale uniqu
patient dispens north american na gener
show continu sign stabil revenu
good copaxon revenu continu slide na revenu
repres y/i declin teva anticip lose addit per year
gener script price pressur gx albuterol also like
neg impact teva proair franchis addit still
debt matur next year
conclus posit sign teva difficulti lay ahead
compani posit return growth chang prior
model reflect guidanc non-gaap ep reduc
competit cgrp space new class drug emerg migrain
space cgrp blocker offer migrain suffer prophylact measur reduc
number migrain nr aimovig first fda approv
may teva lilli nr follow septemb ajovi
emgal respect aimovig sale ramp rather quickli drug grow
three similar drug
monthli price point payer coverag essenti drive growth health
 nr announc cover teva lilli drug exclud
patient use pharmaci benefit manag pbm anoth big three
pbm express script ci nr initi announc cover
lilli howev recent move includ ajovi though may incur
higher pocket cost europ though aimovig approv
eu monthli formul teva may first market quarterli
monthli inject februari chmp recommend ec approv ajovi
final decis expect
debt- strategi teva handl debt
restructur plan compani remain track achiev ex-fx effect
plan spend base reduct teva cash hand meet
matur howev look beyond cash get bit tighter
compani expect question remain
compani grow meet
refin debt gain bit breath room
click full note
report quarter updat prostat cancer
veru report fye sept revenu deriv
busi net loss end period cash
open-label phase prostat cancer enrol data
expect phase trial zuclomiphen citrat enrol data
expect tadfin tablet benign prostat hyperplasia nda
remain track submiss potenti approv
next-gener oral antitubulin alpha beta
oral chemo could serv bridg anti-androgen therapi
resist seen year taxan iv chemotherapi veru initi
evalu treatment mcrpc approv xtandi
nmcrpc follow approv erleada signal us
incorpor anti-androgen treatment paradigm expand larger pc
popul earlier diseas shift soc default significantli
increas opportun potenti bridg therapi
iv chemotherapi trial patient fail anti-androgen xtandi
zytiga on-going data expect primari endpoint reduct
drug veru femal condom preboost desensit wipe
prematur ejacul gener revenu partial offset compani
develop cost urology/oncolog candid reformul exist drug
pathway product address underserv market nich requir
bioequival dissolut studi could reach market
tamsulosin flomax dr bph patient dysphagia tamsulosin xr
capsul food effect bph solifenacin vesicar drg patient
oab dysphagia tadalafil/finasterid cialis-proscar bph ed
updat program expect veru move
click full note
debt financ could extend runway bivgam
approv
announc term loan facil top sharehold
percept advisor loan payabl tranch matur
first tranch use pay exist credit facil
marathon second tranch becom avail either approv
bivigam prior approv supplement pa
loan
debt consolid adma largest sharehold essenti
bring debt in-hous sharehold own
access capit commerci effort around bivigam
expect approv launch year
preclud need near-term equiti financ estim
cash addit minimum draw
would extend runway support launch bivigam and/or
conclus view smart financ strategi manag
best posit compani launch next product pend approv
share trade higher financ announc
today anoth
loan term term loan extend percept advisor divid two
tranch first tranch use pay prior credit
facil associ fee second tranch made avail
either approv pa bivigam approv pdufa
second tranch avail discret june
minimum draw loan interest-onli matur march
borrow incur interest rate libor floor note
current libor addit issu warrant percept
share common stock price warrant adjust provis see
bivigam statu respons submit bivigam receiv
complet respons letter fda drug substanc prior approv
supplement pa bivigam pdufa previous push back
base fda requir addit time review pa prior approv
supplement chang given pa major amend bivigam
bla fda standard procedur built review chang note
fda typic extend review time run decemb
year-end near possibl fda respons send
submit respons fda
track april pdufa rais bivigam-specif issu
parti use bivigam remain good stand nabi-
hb immun globulin product approv market
manufactur facil facil vai voluntari action indic
statu requir drug approv phase data posit
posit safeti profil submiss new bla unrel bivigam
model updat factor debt subsequ interest model assum
second tranch drawn follow pdufa also push
back launch bivigam prior estim adjust near term
expens estim roll metric forward chang pt
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
receiv full disclosur compani maxim group coverag mention report pleas send
